Palumbo Wealth Management’s Protagonist Therapeutics PTGX Stock Holding History

Palumbo Wealth Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$293K	Sell	2,390 -3,693	-61%	-$386K	0.06%	193
2026 Q1	$641K	Sell	6,083 -257	-4%	-$22.8K	0.16%	103
2025 Q4	$554K	Buy	6,340 +1,072	+20%	+$87.7K	0.14%	115
2025 Q3	$350K	Sell	5,268 -2,262	-30%	-$129K	0.11%	119
2025 Q2	$416K	Buy	+7,530	New	+$361K	0.13%	120
2024 Q4	–	Sell	-5,211	Closed	-$234K	–	187
2024 Q3	$234K	Buy	+5,211	New	+$211K	0.09%	126

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Palumbo Wealth Management's PTGX Position: Q2 2026 in Review

Palumbo Wealth Management reduced its Protagonist Therapeutics (PTGX) stake by 61% in Q2 2026, selling an estimated $386K and leaving 2,390 shares worth $293K. The position accounts for 0.06% of the portfolio, ranked #193.

Palumbo Wealth Management first reported a position in PTGX in Q3 2024 and has held it in 6 quarters since. The position peaked at $641K in Q1 2026. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Palumbo Wealth Management held 2,390 shares of Protagonist Therapeutics worth $293K as of Q2 2026.
Palumbo Wealth Management sold 3,693 Protagonist Therapeutics shares in Q2 2026, an estimated $386K.
Protagonist Therapeutics made up 0.06% of Palumbo Wealth Management's portfolio in Q2 2026, its #193 holding.
Palumbo Wealth Management first reported a position in Protagonist Therapeutics in Q3 2024 and has held it in 6 quarters since.
Palumbo Wealth Management's Protagonist Therapeutics position peaked at $641K in Q1 2026.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Palumbo Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.